drugset

drugset / Trial / NCT03979456

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS

NCT03979456 ↗

Phase 3 Unknown 200 enrolled Karolinska Institutet

RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized trial of long-term dosage of rituximab in multiple sclerosis

Timeline

Start: 2018-07-04
Primary completion: 2024-12-20
Completion: 2025-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	500 mg	—

Indications